Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors
NCT00003713 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35
Last updated 2018-08-29
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of intoplicine in treating patients who have advanced or metastatic solid tumors.
Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
Interventions
- DRUG
-
intoplicine
Sponsors & Collaborators
-
Genzyme, a Sanofi Company
lead INDUSTRY
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1997-08-31
Countries
- United States
- Canada
Study Locations
More Related Trials
-
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
NCT00741403 ·Status: COMPLETED ·Phase: PHASE1
-
Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors
NCT00003710 ·Status: COMPLETED ·Phase: PHASE1
-
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors
NCT00820560 ·Status: COMPLETED ·Phase: PHASE1
-
Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00003708 ·Status: COMPLETED ·Phase: PHASE1
-
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
NCT04317105 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies
NCT00121732 ·Status: COMPLETED ·Phase: PHASE1
-
BMS-214662 in Treating Patients With Advanced Solid Tumors
NCT00004877 ·Status: COMPLETED ·Phase: PHASE1
-
Chemotherapy in Treating Patients With Solid Tumors
NCT00003698 ·Status: COMPLETED ·Phase: PHASE1
-
Penclomedine in Treating Patients With Advanced Solid Tumors
NCT00002915 ·Status: COMPLETED ·Phase: PHASE1
-
Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00003703 ·Status: COMPLETED ·Phase: PHASE1
-
Study of PKI-179 Administered Orally to Subjects With Solid Tumors
NCT00997360 ·Status: WITHDRAWN ·Phase: PHASE1
-
BMS-184476 in Treating Patients With Advanced Solid Tumors
NCT00003705 ·Status: COMPLETED ·Phase: PHASE1
-
Irinotecan in Treating Patients With Advanced Solid Tumors
NCT00004051 ·Status: COMPLETED ·Phase: PHASE1
-
SB-743921 In Patients With Solid Tumors
NCT00136513 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.
NCT00046696 ·Status: COMPLETED ·Phase: PHASE1
-
SMP-3124LP in Adults With Advanced Solid Tumors
NCT06526819 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
CCI-779 in Treating Patients With Advanced Solid Tumors
NCT00003712 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
NCT03762447 ·Status: COMPLETED ·Phase: PHASE1
-
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
NCT05098132 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors
NCT00003430 ·Status: COMPLETED ·Phase: PHASE1
-
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
NCT07337525 ·Status: RECRUITING ·Phase: PHASE1
-
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
NCT04780217 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
NCT00006036 ·Status: COMPLETED ·Phase: PHASE1
-
GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors
NCT01313598 ·Status: COMPLETED ·Phase: PHASE1
-
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
NCT02030067 ·Status: COMPLETED ·Phase: PHASE1/PHASE2